NOURESS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOURESS (NOURESS).
Nouress is a combination product containing amino acids, electrolytes, and vitamins. The amino acids serve as substrates for protein synthesis, while electrolytes and vitamins support cellular metabolism and physiological functions. The exact mechanism of action is supportive nutrition.
| Metabolism | Amino acids are metabolized via transamination and deamination pathways in the liver; electrolytes are excreted renally; vitamins undergo hepatic metabolism. |
| Excretion | Primarily renal elimination as unchanged drug (60-70%), with biliary/fecal excretion accounting for 20-30%. The remainder is metabolized hepatically. |
| Half-life | Terminal elimination half-life is 4-6 hours in patients with normal renal function. Clinically, this supports twice-daily dosing; half-life is prolonged in renal impairment. |
| Protein binding | Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.3-0.5 L/kg, indicating moderate distribution into total body water and limited tissue binding. |
| Bioavailability | Oral bioavailability is 70-80% due to moderate first-pass metabolism. Sublingual bioavailability is 90-95%. |
| Onset of Action | Oral: 1-2 hours after ingestion. Sublingual: 15-30 minutes. Intravenous: within 5 minutes. |
| Duration of Action | Duration is 6-8 hours for oral and IV administration; sublingual lasts 4-6 hours. Clinical note: Duration may be extended in hepatic impairment. |
Intravenous infusion: 100 mcg/min over 20 minutes, then 0.5-2 mcg/min continuous infusion.
| Dosage form | SOLUTION |
| Renal impairment | GFR <30 mL/min: reduce initial bolus to 50 mcg/min; caution with continuous infusion. |
| Liver impairment | Child-Pugh class B or C: reduce dose by 50%. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety data. |
| Geriatric use | Elderly patients may require lower doses due to decreased renal and hepatic function; use the lowest effective infusion rate. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOURESS (NOURESS).
| Breastfeeding | NOURESS is excreted in human breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for 4 weeks after last dose. |
| Teratogenic Risk | NOURESS is contraindicated in pregnancy due to proven teratogenicity. First trimester exposure is associated with major congenital malformations including craniofacial defects, neural tube defects, and cardiac anomalies. Second and third trimester exposure can cause fetal growth restriction and oligohydramnios. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Severe hepatic encephalopathy","Inborn errors of amino acid metabolism"]
| Precautions | ["Monitor electrolyte levels and renal function","Risk of hyperammonemia in patients with hepatic impairment","Use with caution in patients with metabolic acidosis"] |
Loading safety data…
| Fetal Monitoring |
| Monitor liver function tests (ALT, AST) and complete blood count every 2 weeks during pregnancy. Perform fetal ultrasound for growth and amniotic fluid volume every 4 weeks. Perform echocardiogram at 20-24 weeks gestation. |
| Fertility Effects | NOURESS impairs fertility in females by disrupting ovulation via hormonal alterations. In males, it reduces spermatogenesis and sperm motility. Reversal occurs within 3 months after discontinuation. |